List of Excipients in Branded Drug 3M SOLUPREP

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
3M Company	3M SOLUPREP	chlorhexidine gluconate and isopropyl alcohol	17518-080	ACETYLTRIBUTYL CITRATE	2026-01-20
3M Company	3M SOLUPREP	chlorhexidine gluconate and isopropyl alcohol	17518-080	FD&C BLUE NO. 1	2026-01-20
3M Company	3M SOLUPREP	chlorhexidine gluconate and isopropyl alcohol	17518-080	FD&C YELLOW NO. 5	2026-01-20
3M Company	3M SOLUPREP	chlorhexidine gluconate and isopropyl alcohol	17518-080	TRISODIUM HEDTA	2026-01-20

3M SoluPrep Excipient Strategy and Commercial Opportunities

Last updated: October 26, 2026

3M SoluPrep is a topical antiseptic platform centered on chlorhexidine gluconate (CHG) and isopropyl alcohol (IPA), primarily for preoperative skin preparation and central-line antisepsis. Its commercial value is driven less by novel excipient chemistry than by formulation stability, rapid antimicrobial activity, applicator design, flammability controls, skin tolerability, packaging, and hospital procurement contracts.

The strongest opportunities are differentiated CHG delivery systems, lower-irritancy formulations, pediatric and neonatal products, residue-management technologies, and contract-manufactured private-label alternatives. The principal barriers are FDA antiseptic requirements, compatibility testing, flammable-liquid logistics, clinical adoption, and Solventum’s established hospital relationships.

What is 3M SoluPrep and what does it contain?

3M SoluPrep is a family of topical antiseptic products formerly marketed by 3M Health Care and now associated with Solventum following the 2024 separation of 3M’s health-care business. Product configurations vary by market and presentation, but CHG/IPA products generally use:

Component	Functional role	Commercial significance
Chlorhexidine gluconate	Primary antiseptic active	Provides persistent antimicrobial activity
Isopropyl alcohol	Rapid antiseptic active and solvent	Produces rapid microbial kill and short drying time
Purified water	Vehicle and concentration modifier	Controls viscosity, solubility and skin feel
Colorant	Visual application and coverage aid	Supports procedural compliance
Packaging materials	Container and applicator system	Controls dose, contamination, leakage and fire risk

Common SoluPrep CHG products are associated with a formulation containing 2% CHG and 70% IPA, although concentrations, applicator sizes and product presentations must be confirmed against the applicable country label. FDA antiseptic products are regulated according to active-ingredient monograph requirements, product labeling and, where applicable, an approved new drug application.

The excipient system has a narrow technical purpose. IPA must remain at a concentration that preserves antimicrobial performance while maintaining acceptable drying and skin tolerability. Water supports CHG solubility and application characteristics. Colorants must remain stable in a high-alcohol environment and must not interfere with clinical visibility or skin safety.

What excipient strategy does SoluPrep use?

SoluPrep’s likely commercial formulation strategy is a simple hydroalcoholic system with limited excipient complexity. That approach provides four advantages:

1. It reduces formulation and manufacturing risk.
2. It supports rapid drying before surgery or catheter placement.
3. It limits the number of inactive ingredients requiring safety and compatibility evaluation.
4. It simplifies global supply and quality control.

Why chlorhexidine and isopropyl alcohol are combined

IPA acts quickly but has limited residual activity. CHG has slower onset but binds to skin and provides persistent antimicrobial activity. The combination allows a manufacturer to position the product around both rapid kill and residual protection.

This combination also creates formulation constraints. High IPA content can increase skin dryness, sting and flammability. CHG can precipitate or lose performance in the presence of incompatible anionic materials. The product must remain chemically stable throughout shelf life, including under elevated temperature, transport stress and repeated manufacturing-scale filling.

What excipients could improve SoluPrep-type products?

Commercially relevant excipient development should focus on performance rather than adding inactive ingredients for differentiation.

Excipient or formulation approach	Potential benefit	Main risk
Humectants such as glycerol or propylene glycol	May reduce skin dryness	Can slow drying and alter antimicrobial kinetics
Mild emollients	May improve skin tolerability	Can impair wetting, residue removal or surgical adhesion
Buffer systems	May improve CHG stability	pH changes can affect skin compatibility and preservative performance
Alternative colorants	Improve visibility or reduce staining	Colorant stability and regulatory review
Low-residue surfactants	Improve wetting on oily or irregular skin	Potential irritation or CHG incompatibility
Polymer-based film formers	Extend persistence and reduce wash-off	May delay drying or interfere with dressings
Reduced-IPA systems	Lower flammability and irritation	May reduce kill speed and alter regulatory positioning

A successful formulation must preserve microbial efficacy, drying time, skin compatibility, package integrity and clinical workflow. In hospital antisepsis, a formulation that requires extra rubbing, wiping or drying time can lose commercial value even if laboratory efficacy is strong.

What formulations are protected by SoluPrep intellectual property?

Publicly available product information supports a formulation and applicator strategy, but it does not establish a complete, current list of enforceable SoluPrep patents. Product-specific patent coverage can involve separate rights for:

• CHG/IPA composition ranges;
• colorant systems;
• applicator reservoirs and sponge materials;
• metered-dose delivery;
• packaging that limits evaporation;
• fire-safety and spill-control features;
• combination kits for surgical or catheter procedures;
• manufacturing and filling processes.

The commercial product may also rely on trademarks, regulatory know-how, quality systems, clinical evidence and purchasing agreements that are more important than composition patents.

A patent search should separate 3M Health Care filings from post-spin-off Solventum ownership and should check assignment records, terminal disclaimers, maintenance fees and expiration status. The absence of a visible patent number on a product page does not establish that the product has no related patent rights.

How strong is the SoluPrep patent estate?

The likely patent strength is mixed:

Asset type	Expected strength	Reason
Broad CHG/IPA composition	Low to moderate	Active ingredients and common concentration ranges may be difficult to claim broadly
Narrow concentration and excipient claims	Moderate	Specific stability, compatibility or skin-tolerability data can support narrower claims
Applicator architecture	Moderate to strong	Device geometry, dose control and packaging can create enforceable differentiation
Kit and procedure claims	Moderate	Claims may target a defined clinical workflow or combination
Manufacturing process	Moderate	Process claims can be difficult to detect but may be valuable if non-obvious
Trademark and procurement position	Strong commercially	Brand recognition and hospital contracts can deter switching without patent enforcement

For a competitor, the most practical freedom-to-operate strategy is usually to avoid the branded applicator configuration and develop an independently supported formulation, container and application system.

When does SoluPrep lose exclusivity?

SoluPrep does not have a single exclusivity date comparable to a patented small-molecule prescription drug. The relevant exclusivity layers are separate.

Exclusivity layer	Relevance to SoluPrep
Drug patent term	Applies only to valid, unexpired claims covering a formulation, method or device
FDA exclusivity	Depends on the regulatory pathway and product status
OTC monograph framework	May permit compliant competing products without reliance on SoluPrep’s brand
Trademark protection	Can continue while the mark remains valid and used
Trade secrets	No fixed expiration if maintained confidentially
Procurement contracts	Expire or renew according to hospital and group-purchasing terms
Clinical adoption	Can persist after legal exclusivity ends

CHG topical antiseptics have historically operated within a complex regulatory environment involving monographs, approved applications and product-specific FDA actions. FDA’s final rule for OTC topical antiseptic products established requirements for active ingredients, labeling and safety data, but product status must be evaluated against the current FDA regulatory record rather than inferred from the commercial name.[1]

What is the FDA regulatory status of 3M SoluPrep?

SoluPrep is a topical antiseptic drug product, often delivered through a disposable applicator that may also be regulated as a device. The active drug portion and the applicator can therefore raise different compliance issues.

Key regulatory questions include:

• Whether the specific product is marketed under an FDA-approved application;
• Whether its active ingredients and concentrations conform to the applicable OTC monograph;
• Whether the product is listed in FDA’s drug registration and listing databases;
• Whether the applicator is cleared, exempt or incorporated into the drug product presentation;
• Whether the product has labeling limitations for neonates, premature infants or damaged skin;
• Whether flammability warnings and surgical-use instructions meet FDA requirements.

FDA has required extensive safety and efficacy evaluation for topical antiseptic active ingredients, including CHG. The regulatory status of a particular SoluPrep SKU should be determined by National Drug Code, labeler and formulation, not by the product family name alone.[2]

Does SoluPrep have Orange Book patents?

SoluPrep is not ordinarily analyzed like a conventional prescription drug with a standard Orange Book patent-and-exclusivity profile. Orange Book relevance depends on whether the specific product is approved under an NDA or ANDA and whether patent information has been submitted for that application.

For a CHG/IPA antiseptic marketed under an OTC framework, the main competitive issue is usually monograph compliance rather than an Orange Book Paragraph IV challenge. A competitor may therefore enter with its own compliant product without certifying against SoluPrep patents, unless the reference product’s approval pathway creates a listed patent framework.

Which companies are challenging SoluPrep commercially?

Competition is likely to come from established surgical-prep and antiseptic manufacturers rather than from a single patent challenger. Relevant competitors and adjacent suppliers include:

• BD, including ChloraPrep-branded products;
• Cardinal Health private-label and hospital-supply products;
• Medline Industries;
• Ecolab and related infection-prevention suppliers;
• Mölnlycke;
• Dynarex;
• PDI;
• generic and private-label CHG/IPA manufacturers.

The most direct competitive comparison is with ChloraPrep, which also uses CHG and alcohol in a procedural skin-preparation platform. Competition centers on CHG concentration, alcohol concentration, applicator size, drying time, staining, skin reactions, packaging, price and hospital formulary status.

How does SoluPrep compare with ChloraPrep?

Commercial factor	SoluPrep	ChloraPrep
Core positioning	Surgical and procedural antisepsis	Surgical and procedural antisepsis
Typical active combination	CHG plus IPA in relevant products	CHG plus IPA in relevant products
Primary differentiation	3M/Solventum applicator and hospital portfolio	BD applicator, clinical familiarity and portfolio
Key buyer criteria	Price, drying, coverage, safety, supply	Price, clinical evidence, coverage and supply
Main switching barrier	Workflow familiarity and contracts	Workflow familiarity and contracts
Patent value	Likely concentrated in delivery and formulation details	Likely concentrated in product, applicator and process details

A competitor can win share without superior excipient technology if it offers lower total acquisition cost, reliable supply, a comparable applicator, favorable group-purchasing terms or a formulation that addresses skin irritation.

What commercial opportunities exist in SoluPrep excipient development?

1. Pediatric and neonatal formulations

Neonatal and pediatric use creates demand for reduced sting, lower residue and more controlled application. The opportunity is technically difficult because lowering IPA or adding emollients can affect antimicrobial performance and drying time. A product supported by age-specific safety evidence could command a premium.

2. Lower-irritancy adult products

Hospitals need repeated-use antisepsis for catheter care, dialysis access and procedural preparation. A lower-drying formulation could target patients with fragile or compromised skin. The formulation must demonstrate that skin benefits do not compromise microbial reduction or dressing adhesion.

3. Low-residue formulations

Residue can affect surgical drapes, dressings, adhesive securement and visual inspection. A low-residue CHG/IPA product could compete in operating rooms and vascular-access procedures if it maintains coverage and drying speed.

4. Improved applicators

The highest-value opportunity may be the delivery system rather than the excipient. Potential innovations include:

• Dose-controlled applicators;
• Applicators optimized for small pediatric sites;
• Spill-resistant reservoirs;
• Longer contact-time delivery;
• Reduced-drip designs;
• Applicators with clearer visual coverage;
• Packaging that reduces IPA evaporation;
• Kits combining antiseptic, drying time controls and dressing components.

5. Private-label and contract manufacturing

Hospitals and distributors may seek alternatives to branded SoluPrep and ChloraPrep. A contract manufacturer could offer a compliant CHG/IPA product with a private-label applicator, provided it can demonstrate formulation stability, microbial performance, packaging integrity and regulatory compliance.

6. Geographic expansion

The strongest geographic opportunities are markets with rising surgical volumes, central-line use and infection-prevention standards. Regulatory requirements differ materially across the United States, European Union, Canada, Japan and emerging markets. A formulation designed for global use should address:

• CHG concentration limits;
• Alcohol labeling;
• Flammability rules;
• Pediatric restrictions;
• Colorant approvals;
• Biocidal-product requirements in Europe;
• Local clinical-evidence expectations;
• Language and packaging requirements.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are substantial despite the apparent simplicity of the formulation.

High-priority controls include:

• Accurate CHG and IPA concentration;
• Homogeneous mixing;
• Control of evaporation during filling;
• Compatibility between IPA and plastic components;
• Prevention of container stress cracking;
• Stability of colorants;
• Microbial control in the aqueous phase;
• Applicator dose uniformity;
• Seal integrity;
• Flammability controls;
• Batch-to-batch skin-compatibility performance.

The most defensible intellectual property may cover the interaction between formulation and applicator. A composition claim alone may be vulnerable if it relies on well-known actives and conventional solvents. A stronger portfolio would combine narrow formulation ranges with data showing unexpected stability, reduced irritation, faster drying, lower residue or improved dressing adhesion.

What patent litigation and Paragraph IV risks exist?

No specific SoluPrep Paragraph IV challenge or active patent litigation should be assumed without a verified court docket, FDA listing or patent record tied to the exact product and sponsor.

The more realistic litigation risks are:

• Patent disputes involving applicator design;
• Trade-secret claims involving filling or packaging processes;
• Trademark disputes over SoluPrep branding;
• Product-liability claims involving burns, irritation or flammability;
• Contract disputes involving hospital and group-purchasing agreements;
• Regulatory enforcement involving labeling or manufacturing controls.

A generic entrant’s launch risk is therefore likely to depend more on regulatory classification, product liability, clinical acceptance and supply reliability than on a conventional Orange Book patent certification.

What revenue exposure does SoluPrep represent?

Public sources do not provide a separately reported SoluPrep revenue figure. Solventum reports broader health-care business results rather than a product-level SoluPrep breakdown in standard public filings.[3]

Revenue exposure is concentrated in institutional channels:

• Operating-room procedures;
• Central-line insertion and maintenance;
• Catheterization;
• Dialysis;
• Emergency and inpatient care;
• Ambulatory surgery;
• Distributor and group-purchasing contracts.

A competing product can erode revenue through formulary conversion even without defeating a patent. The most important commercial metrics are hospital account retention, units per procedure, average selling price, applicator mix, contract renewal rates and conversion cost.

What generic launch scenarios exist for SoluPrep?

Launch scenario	Likely market effect	Main requirement
Exact-comparable CHG/IPA product	Price pressure	Regulatory compliance and reliable supply
Lower-cost private label	Distributor and hospital substitution	Contract manufacturing and procurement access
Pediatric or neonatal product	Premium niche	Strong safety package
Low-irritancy formulation	Selective clinical adoption	Comparative skin-tolerability data
Improved applicator	Defensible differentiation	Device and formulation validation
Alcohol-free or reduced-alcohol product	Alternative-use segment	Proof of equivalent clinical performance
Combination antiseptic kit	Higher account value	Packaging, regulatory and workflow integration

The fastest route to commercial entry is usually a compliant comparable product using an independently designed applicator. The highest-margin route is a differentiated product supported by clinical data and a defined unmet need.

Key Takeaways

• SoluPrep is primarily a CHG/IPA antiseptic and delivery-system platform.
• Its excipient strategy is likely intentionally simple, with IPA, water and limited supporting ingredients.
• The strongest formulation opportunities involve skin tolerability, residue reduction, pediatric use and controlled drying.
• Applicator and packaging patents may be more commercially important than broad composition patents.
• SoluPrep does not have one universal patent-expiration date.
• Orange Book and Paragraph IV analysis depends on the exact FDA approval pathway and product SKU.
• The main competitive threat is a compliant private-label or branded alternative with lower cost, stronger supply or better workflow fit.
• Product-level SoluPrep revenue is not separately disclosed in public Solventum reporting.
• Manufacturing barriers include IPA evaporation, container compatibility, dose uniformity, flammability and stability.
• A credible launch strategy requires regulatory compliance, hospital procurement access and evidence that the formulation performs at least as well as established CHG/IPA products.

Frequently Asked Questions

Is SoluPrep a prescription drug or an over-the-counter antiseptic?

SoluPrep is a topical antiseptic product. Its regulatory pathway depends on the specific formulation, sponsor and market. It should not be classified solely from the brand name.

Can a company make a generic version of SoluPrep?

A company may develop a competing CHG/IPA antiseptic if it satisfies the applicable FDA or non-U.S. regulatory requirements and avoids enforceable patent, trademark and device claims.

Are the inactive ingredients in SoluPrep patentable?

Yes. Specific excipient combinations, concentration ranges, stability systems, colorant systems and formulation-applicator interactions may be patentable if they satisfy novelty, non-obviousness and enablement requirements.

What is the most valuable SoluPrep product improvement?

The most commercially valuable improvement is likely a validated delivery system that reduces irritation or residue while preserving rapid antimicrobial activity, drying time and dressing compatibility.

Is CHG/IPA formulation technology difficult to manufacture?

Yes. The formulation is chemically straightforward but operationally demanding. IPA evaporation, plastic compatibility, flammability, filling accuracy, applicator performance and long-term stability require specialized controls.

References

1. U.S. Food and Drug Administration. (2020). Safety and effectiveness of consumer antiseptic rubs; topical antimicrobial drug products for over-the-counter human use. Federal Register.

2. U.S. Food and Drug Administration. (2023). OTC Monograph M003: Topical antiseptic drug products for over-the-counter human use. FDA.

3. Solventum. (2024). Annual report and health-care business disclosures. Solventum Corporation.

4. U.S. Food and Drug Administration. (n.d.). Drug databases and drug listing information. FDA.

5. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.